Less than six months after winning a $36 million National Institutes of Health (NIH) contract for respiratory antibiotic TP-271, Tetraphase Pharmaceuticals Inc. landed a $67 million BARDA contract for broad-spectrum antibiotic TP-434. Read More
The 800-pound gorilla in the Patent and Trademark Office (PTO) hearing on genetic diagnostic tests was Myriad Genetics Inc. – even though the Salt Lake City-based company wasn't on the agenda. Read More
Protalix Biotherapeutics Inc., of Carmiel, Israel, priced a public offering of 4.5 million shares at $5.25 per share, a 14.3 percent discount to Wednesday's closing price, which will bring in about $23.6 million in gross proceeds. Read More
BioWorld's offices will be closed Monday, Feb. 20, in observance of the President's Day holiday in the U.S. No issues will be published that day. Read More
• Cleveland BioLabs Inc., of Buffalo, N.Y., said results of the first structural and biophysical study of Toll-like receptor 5 (TLR5)/flagellin interaction help to decipher the molecular mechanisms underlying TLR5 recognition and signaling by CBLB502, an optimized derivative of bacterial flagellin and the company's candidate in development as a radiation countermeasure and a cancer therapeutic agent. Read More
• Curis Inc., of Lexington, Mass., said partner Debiopharm Group, of Lausanne, Switzerland, initiated a Phase Ib expansion study of Debio 0932, a heat-shock protein 90 inhibitor that recently completed a Phase Ia dose-escalation study evaluating safety and maximum-tolerated dose. Read More
